We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DynoChem Extends Software Agreement with Bristol-Myers Squibb
News

DynoChem Extends Software Agreement with Bristol-Myers Squibb

DynoChem Extends Software Agreement with Bristol-Myers Squibb
News

DynoChem Extends Software Agreement with Bristol-Myers Squibb

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DynoChem Extends Software Agreement with Bristol-Myers Squibb"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DynoChem Inc. has announced that it had entered into a global, multi-year licensing and support agreement with Bristol-Myers Squibb.

The agreement will allow Bristol-Myers Squibb to expand deployment of DynoChem process modeling software throughout its Research and Development group and for scale-up into manufacturing.

Bristol-Myers Squibb noted that in meeting the challenges inherent in the scale-up of synthetic pharmaceutical processes, operation modeling allows the company to make use of knowledge and resources to answer critical questions.

In addition, the incorporation of modeling technologies such as DynoChem across Bristol-Myers Squibb’s process development enterprise helps achieve the company’s development goals.

PFD Managing Director Dr. Joe Hannon said, “We are pleased to have the opportunity to expand our relationship with BMS and continue our commitment to their pharmaceutical product development effort. We believe this agreement further validates DynoChem’s success in achieving our customers’ goals of accelerating process development and lowering drug development costs.”

Advertisement